EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Hemosphere, Inc., developer of the HeRO® Graft for hemodialysis access, announced that another sales record was achieved. Last week, Hemosphere sold the 4000 ...

The HeRO Graft is a proprietary graft-based solution for end-stage renal disease hemodialysis patients with limited access options and central venous stenosis.

The company’s current portfolio of dialysis therapies includes HeRO Graft, an access device for patients who are failing fistulas or grafts or are catheter-dependent due to the blockage of veins ...